Caliper Life Sciences Reports First Quarter 20...(nd our ability to lowerlegal expenses ov...),Health

Date:5/8/2008

nd our ability to lower legal expenses over the remainder of 2008, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward- looking statements as a result of a number of factors, including that Caliper's expectations regarding demand for its products and services may not materialize if capital spending by Caliper's customers declines, if competitors introduce new competitive products, or if Caliper is unable to convince potential customers regarding the superior performance of its drug discovery and imaging systems and other products. Further information on risks faced by Caliper are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2007. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release or the conference call.

NOTE: Caliper is a registered trademark of Caliper Life Sciences, Inc.

CALIPER LIFE SCIENCES, INC.

SELECTED FINANCIAL INFORMATION

(unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

Three Months Ended

March 31,

2008 2007

Revenue:

Product revenue $17,665 $15,261

Service revenue 9,008
'/>"/>

SOURCE Caliper Life Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results
2. Caliper Life Sciences Ships 500th IVIS Imaging System
3. Derma Sciences Announces Date of Its First Quarter 2008 Earnings Release and Conference Call on May 15, 2008
4. Applied Precision Announces Sale of Life Sciences Business Unit to Senior Management and Telegraph Hill Partners
5. Argonnes Crabtree Elected to National Academy of Sciences
6. 2 NYU faculty elected to National Academy of Sciences
7. Derma Sciences Receives Third FDA Clearance for MEDIHONEY(TM) Wound & Burn Dressings
8. Arkion(R) Life Sciences Receives Crisis Exemption to US EPA Section 18 Approval in Mississippi and Tennessee to Market Avitec Corn Seed Treatment
9. Microsoft Health & Life Sciences Developer and Solutions Conference to Feature the Latest Microsoft-Based Software Solutions
10. Life Sciences Fund grants awards to launch health research
11. Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program